Amyloidosis Research Consortium

The Amyloidosis Research Consortium (ARC) is a non-profit organization founded in 2015. ARC’s mission is dedicated to transforming the way research is being done and focuses on what will have the greatest impact on improving the lives of amyloidosis patients. We forge collaborations across industry, research, clinical care and regulatory to more rapidly advance the discovery of new treatments. ARC empowers and supports patients by making sure they have access to the best quality of care and information.

Amyloidosis is the term for a group of rare diseases in which an abnormal protein misfolds and deposits as amyloid in organs and tissues, causing damage and eventually organ failure. There are different types of amyloidosis, and they vary from one another in their biochemical nature and natural history. Some are acquired, and others inherited. In the United States, approximately 4,000 people develop Amyloidosis each year. It is currently thought to be very underdiagnosed and therefore that number is expected to rise significantly.

To learn more about ARC, visit http://www.arci.org